When does SNT.AX stock report earnings and what matters most

SNT.AX earnings are announced on **06 Feb 2026**. Investors should watch cash runway, R&D spend, and clinical updates on amsulostat, since those items most directly affect valuation and near-term share moves.

What is Meyka AI's short-term forecast for SNT.AX stock

Meyka AI's forecast model projects **A$0.04** near term, implying **~14.29%** upside from **A$0.035**. Forecasts are model projections and not guarantees.

What are the main risks for SNT.AX stock investors

Main risks include negative clinical data, dilution from capital raises, and low liquidity which can magnify price swings. Clinical-stage biotech risk is binary and outcomes drive re-ratings.

How does SNT.AX stock compare to the ASX Healthcare sector

SNT.AX is a clinical-stage developer with negative earnings and lower valuation metrics versus larger healthcare peers. Sector peers trade higher PE and PB due to stable revenues and profitability.

AU Stocks

SNT.AX Syntara Limited pre-market 04 Feb 2026: Feb 6 earnings will test clinical progress

ByHuzaifa Zahoor February 4, 2026

SNT.AX stock trades at A$0.035 as we head into the pre-market session on 04 Feb 2026, with an earnings announcement scheduled for 06 Feb 2026. The price jumped +9.38% on recent data to A$0.035 on volume 1,901,127.00, signalling investor attention ahead of clinical and financial updates. Syntara Limited (ASX: SNT.AX) is a clinical-stage healthcare developer; upcoming commentary on trial progress for amsulostat may drive near-term volatility and re-rating opportunities.